Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 12,226 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Spinal Muscular Atrophy
Interventions: Risdiplam, Midazolam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: ascorbic acid, bortezomib, melphalan; Dietary Supplement · Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 8
States / cities: Fresno, California • Orange, California • West Hollywood, California + 5 more

Conditions: Gaucher Disease, Type 1
Interventions: Eliglustat tartrate, Imiglucerase; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 17
States / cities: Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Asthma
Interventions: Fluticasone furoate 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Long Beach, California • Los Angeles, California • Newport Beach, California + 7 more

Conditions: Chronic Conditions, Multiple
Interventions: ET-Text (Laptop), ET-Voice (Smart System); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Relapsing Multiple Sclerosis
Interventions: Ocrelizumab, Platform; Drug
Lead sponsor: Georgia State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation; Genetic · Radiation
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 10
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Multiple Sclerosis
Interventions: Factors that influence compliance; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Multiple Myeloma
Interventions: First-line therapy, Second-line Multiple Myeloma treatments; Other · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 3,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 252
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 60 Years and older
Enrollment: 1,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 18
States / cities: Mobile, Alabama • Phoenix, Arizona • Riverside, California + 15 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: GLPG1690, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 40 Years and older
Enrollment: 781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Graft Versus Host Disease
Interventions: GLASSIA, methylprednisolone or equivalent steroid, Albumin; Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: HIV Infections
Interventions: VH4004280, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Posttraumatic Stress Disorder
Interventions: Therapy, Midomafetamine, Placebo; Behavioral · Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Boulder, Colorado + 7 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Wobe-Mugos E, melphalan, prednisone, quality-of-life assessment; Drug · Procedure
Lead sponsor: Medsearch; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 15 more

Conditions: Psoriasis Vulgaris
Interventions: PTH (1-34) Gel / Placebo Gel; Drug
Lead sponsor: Manhattan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: San Diego, California • Ormond Beach, Florida • Fridley, Minnesota + 1 more

Conditions: Atopic Dermatitis
Interventions: delgocitinib; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 2 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 9 more

Conditions: Age-Related Maculopathy
Interventions: RN6G, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 83
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Conditions: B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions: EB103; Biological
Lead sponsor: Estrella Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Sacramento, California • Cleveland, Ohio • Portland, Oregon + 2 more

Conditions: Dravet Syndrome
Interventions: EPX-100 (Clemizole Hydrochloride), Placebos; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Stroke, Hemiparesis
Interventions: Traditional CI Therapy, Gaming CI Therapy, Gaming CI Therapy with Additional Contact via Video Conference, Traditional Occupational Therapy/Physical Therapy; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Birmingham, Alabama • Columbia, Missouri • Columbus, Ohio + 1 more

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Metastatic Renal Cell Carcinoma
Interventions: AGS-16C3F, Axitinib; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 20
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 16 more

Search by objective public record fields.

A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

ElderTree Via a Voice Activated Device for Managing Chronic Health Conditions (NHLBI)

Effects of Ocrevus in Relapsing Multiple Sclerosis

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis

Connect® MM- The Multiple Myeloma Disease Registry

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Effectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity Rehabilitation

A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma